Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure

• US 20090312532A1
• Filed: 04/21/2006
• Published: 12/17/2009
• Est. Priority Date: 04/22/2005
• Status: Abandoned Application

• Current Assignee: Academisch Ziekenhuis Leiden
• Original Assignee: Academisch Ziekenhuis Leiden
• Inventors: Aartsma-Rus, Annemieke, Van Deutekom, Judith Christina Theodora, Van Ommen, Garrit-Jan Boudewijn
• Application Number:
  US11/919,248
• Publication Number:
  US 20090312532A1
• Time in Patent Office: Days
• US Class Current: 536/23.100
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/3521 Methyl

Abstract

The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the binding of an SR protein and/or methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.

Claims

1. A method for generating an oligonucleotide, the method comprising:

determining a binding site or putative binding site for an SR (Ser-Arg) protein in RNA of an exon, and

producing an oligonucleotide that is complementary to said RNA and that at least partially overlaps said binding site or putative binding site.

2. The method according to claim 1, further comprising

determining from a secondary structure of said RNA, a region that is hybridized to another part of said RNA (closed structure) and a region that is not hybridized in said structure (open structure), and

subsequently generating an oligonucleotide that at least partially overlaps said binding site or putative binding site and that overlaps at least part of said closed structure and overlaps at least part of said open structure.

3. The method according to claim 2, wherein said open and closed structures are adjacent to each other.

4. The method according to claim 1, wherein said oligonucleotide is complementary to a consecutive part of between 14 and 50 nucleotides of said RNA.

5. The method according to claim 1, wherein said oligonucleotide comprises RNA.

6. The method according to claim 1, wherein said oligonucleotide is 2′

-O-methyl RNA and has a full-length phosphorothioate backbone.

7. The method according to claim 1, wherein pre-mRNA comprising said exon exhibits undesirable splicing in a subject.

8. The method according to claim 7, wherein the absence of said exon from mRNA produced from said pre-mRNA, generates a coding region for a protein.

9. The method according to claim 7, wherein the gene from which said RNA comprising said exon is transcribed, encodes an aberrant Duchenne muscular dystrophy gene (DMD), a collagen VI alpha 1 gene (COL6A1), a myotubular myopathy 1 gene (MTM1), a dysferlin gene (DYSF), a laminin-alpha 2 gene (LAMA2), an Emery-Dreyfus muscular dystrophy gene (EMD), and/or a calpain 3 gene (CAPN3).

10. The method according to claim 9, wherein said gene is the Duchenne muscular dystrophy gene.

11. The method according to claim 1, wherein said SR protein is SF2/ASF or SC35 or SRp40 .

12. The method according to claim 10, wherein said exon comprises exon 8, 46, 48, 52, 54-56, 58, 60-63 or 71-78.

13. An oligonucleotide generated by the method according to claim 1.

15. A method for at least partially altering recognition of an exon in a pre-mRNA, the method comprising:

interacting the pre-mRNA with the oligonucleotide of claim 13 so as to at least in part alter recognition of the exon.

19. The method according to claim 15, wherein exon skipping is induced in the pre-mRNA.

14. An oligonucleotide comprising the sequence as depicted in Table 2 or an equivalent thereof.

20. A method for altering exon-recognition in a pre-mRNA, the method comprising:

interacting the pre-mRNA with the oligonucleotide or equivalent thereof of claim 14, so as to alter exon-recognition in the pre-mRNA

16. (canceled)

17. (canceled)

18. (canceled)

21. A method for altering the efficiency with which an exon in a pre-mRNA is recognized by a splicing machinery, said pre-mRNA being encoded by a gene comprising at least two exons and at least one intron, said method comprising:

providing a transcription system comprising said splicing machinery and said gene, with a first oligonucleotide selected from the group consisting of an oligonucleotide comprising the sequence as depicted in Table 2 and an oligonucleotide generated by a method comprising determining a binding site or putative binding site for an SR (Ser-Arg) protein in RNA of an exon and producing an oligonucleotide that is complementary to said RNA and that at least partially overlaps said binding site or putative binding site, wherein said first oligonucleotide is capable of hybridizing to at least one of said exons, and

allowing for transcription and splicing to occur in said transcription system.

22. The method according to claim 21, wherein said gene comprises at least 3 exons.

23. The method according to claim 21, further comprising:

providing said transcription system with at least a second oligonucleotide capable of hybridizing to at least another of said exons.

24. The method according to claim 23, wherein said first oligonucleotide and said second oligonucleotide are physically linked to each other.